Invivyd (NASDAQ:IVVD) Insider Jill Andersen Sells 34,939 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 34,939 shares of Invivyd stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $55,203.62. Following the completion of the transaction, the insider directly owned 181,736 shares of the company’s stock, valued at approximately $287,142.88. This trade represents a 16.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jill Andersen also recently made the following trade(s):

• On Tuesday, February 17th, Jill Andersen sold 32,771 shares of Invivyd stock. The shares were sold at an average price of $1.54, for a total value of $50,467.34.

Invivyd Stock Performance

Shares of IVVD stock opened at $1.65 on Thursday. The company has a market cap of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60. The stock has a 50 day simple moving average of $2.19 and a two-hundred day simple moving average of $1.75. Invivyd, Inc. has a fifty-two week low of $0.46 and a fifty-two week high of $3.07.

Analyst Ratings Changes

A number of equities research analysts have commented on IVVD shares. BTIG Research restated a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. HC Wainwright increased their price target on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, D. Boral Capital reissued a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Invivyd has a consensus rating of “Hold” and an average price target of $8.00.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Negative Sentiment: Jill Andersen sold 34,939 shares on Feb. 18 at an average price of $1.58 (≈$55.2k); her holdings fell ~16.1% to 181,736 shares. SEC Filing
• Negative Sentiment: Jill Andersen sold 32,771 shares on Feb. 17 at $1.54 (≈$50.5k); that trade reduced her position by ~13.1%. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake declined ~15.1% to 117,717 shares. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his ownership fell ~12.4%. SEC Filing
• Negative Sentiment: William E. Duke (CFO) sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake dropped ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: William E. Duke sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his position fell ~13.3%. SEC Filing
• Negative Sentiment: Julie Green sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); her holdings declined ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: Julie Green sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); that trade lowered her stake ~13.3%. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 19,392 shares on Feb. 18 at $1.58 (≈$30.6k); his holdings fell ~14.5% to 114,487 shares. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 18,189 shares on Feb. 17 at $1.54 (≈$28.0k); his position declined ~12.0%. SEC Filing

Institutional Trading of Invivyd

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC purchased a new position in shares of Invivyd during the fourth quarter valued at approximately $53,809,000. BVF Inc. IL bought a new position in Invivyd during the 4th quarter valued at $48,227,000. RA Capital Management L.P. purchased a new position in Invivyd during the 3rd quarter worth $18,831,000. ADAR1 Capital Management LLC bought a new stake in shares of Invivyd in the 3rd quarter worth $8,108,000. Finally, Janus Henderson Group PLC grew its stake in shares of Invivyd by 28.2% in the 4th quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock worth $80,870,000 after acquiring an additional 7,160,065 shares in the last quarter. 70.36% of the stock is owned by institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.